argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment…
News
Trevena Reports Second Quarter 2022 Results and Provides Business Update
OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION…
Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second…
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid…
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration…
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and…
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights
ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing…
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential…
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in…
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
— Strong cash position with $54.8 million of cash and cash equivalents as of June 30,…
ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress
MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (NASDAQ: ASLN),…
Acasti Pharma Reports First Quarter 2023 Operational Results
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Aug. 11, 2022 (GLOBE…
Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent…
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
Topline data from 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver…
RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update
— Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter…
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the…
Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
—Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022– –The…
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis);…